Jeffrey M Leiden is Executive Chairman of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 24,027 shares of VRTX, which is worth approximately $10.4 Million. The most recent transaction as insider was on Dec 04, 2025, when has been sold 1 shares (Common Stock) at a price of $91.05 per share, resulting in proceeds of $91. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24K
0% 3M change
140.41% 12M change
Total Value Held $10.4 Million

JEFFREY M LEIDEN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 04 2025
BUY
Exercise of conversion of derivative security
$91 $91.05 p/Share
1 Added 0.0%
24,027 Common Stock
Dec 03 2025
SELL
Open market or private sale
$28,554,753 $447.7 p/Share
63,781 Reduced 72.64%
24,026 Common Stock
Dec 03 2025
BUY
Exercise of conversion of derivative security
$5,518,332 $86.52 p/Share
63,781 Added 42.08%
87,807 Common Stock
Nov 14 2025
SELL
Open market or private sale
$23,651,156 $441.22 p/Share
53,604 Reduced 69.05%
24,026 Common Stock
Nov 14 2025
BUY
Exercise of conversion of derivative security
$4,759,499 $88.79 p/Share
53,604 Added 40.85%
77,630 Common Stock
Nov 13 2025
SELL
Open market or private sale
$8,675,123 $440.63 p/Share
19,688 Reduced 45.04%
24,026 Common Stock
Nov 13 2025
BUY
Exercise of conversion of derivative security
$1,792,592 $91.05 p/Share
19,688 Added 31.05%
43,714 Common Stock
Feb 14 2025
SELL
Payment of exercise price or tax liability
$2,811,348 $463.46 p/Share
6,066 Reduced 20.16%
24,026 Common Stock
Feb 13 2025
SELL
Payment of exercise price or tax liability
$1,138,345 $450.83 p/Share
2,525 Reduced 7.74%
30,092 Common Stock
Feb 12 2025
BUY
Grant, award, or other acquisition
-
7,209 Added 18.1%
32,617 Common Stock
Feb 04 2025
BUY
Grant, award, or other acquisition
-
15,414 Added 37.76%
25,408 Common Stock
Aug 30 2024
SELL
Open market or private sale
$1,888,216 $499.0 p/Share
3,784 Reduced 27.46%
9,994 Common Stock
Feb 20 2024
SELL
Payment of exercise price or tax liability
$1,731,948 $420.58 p/Share
4,118 Reduced 23.01%
13,778 Common Stock
Feb 15 2024
SELL
Open market or private sale
$1,951,189 $419.16 p/Share
4,655 Reduced 20.64%
17,896 Common Stock
Feb 14 2024
SELL
Open market or private sale
$1,825,338 $419.04 p/Share
4,356 Reduced 16.19%
22,551 Common Stock
Feb 13 2024
SELL
Open market or private sale
$308,898 $419.13 p/Share
737 Reduced 2.67%
26,907 Common Stock
Feb 12 2024
SELL
Open market or private sale
$1,115,015 $419.81 p/Share
2,656 Reduced 8.77%
27,644 Common Stock
Feb 09 2024
SELL
Payment of exercise price or tax liability
$3,402,211 $422.74 p/Share
8,048 Reduced 20.99%
30,300 Common Stock
Feb 08 2024
SELL
Payment of exercise price or tax liability
$1,137,827 $421.73 p/Share
2,698 Reduced 6.57%
38,348 Common Stock
Feb 07 2024
BUY
Grant, award, or other acquisition
-
7,707 Added 15.81%
41,046 Common Stock
Feb 06 2024
BUY
Grant, award, or other acquisition
-
30,916 Added 48.11%
33,339 Common Stock
Jan 08 2024
SELL
Open market or private sale
$2,785,977 $419.07 p/Share
6,648 Reduced 73.29%
2,423 Common Stock
Dec 13 2023
SELL
Open market or private sale
$5,338,929 $399.8 p/Share
13,354 Reduced 59.55%
9,071 Common Stock
Oct 16 2023
SELL
Open market or private sale
$4,847,788 $374.0 p/Share
12,962 Reduced 36.63%
22,425 Common Stock
May 08 2023
SELL
Open market or private sale
$392,625 $349.0 p/Share
1,125 Reduced 3.08%
35,387 Common Stock
JML

Jeffrey M Leiden

Executive Chairman
Boston, MA

Track Institutional and Insider Activities on VRTX

Follow VERTEX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX